Related Experiment Video
Updated: Aug 11, 2026
11:48
Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
MDM2 splice variants and their therapeutic implications
1Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38112, USA. linda.harris@stjude.org
Current Cancer Drug Targets
|February 22, 2005
Summary
MDM2 splice variants are linked to cancer progression but have contradictory functions. Their role in tumor development and as therapeutic targets requires further investigation due to complex p53 interactions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MDM2 splice variants are found in various tumors and linked to advanced disease.
- Their precise role in tumorigenesis and therapeutic potential remains unclear due to conflicting data.
Purpose of the Study:
- To investigate the contradictory functions of MDM2 splice variants in cancer.
- To explore the mechanisms underlying MDM2 splice variant-mediated effects on tumor development and cell growth.
Main Methods:
- Utilized transgenic mouse models (MDM2-B and Emu-myc) to study splice variant expression in vivo.
- Conducted in vitro experiments to assess the impact of splice variants on cell growth and p53 interactions.
Main Results:
- In vivo studies showed MDM2 splice variants promote tumor development.
- In vitro, splice variants induced p53-dependent growth inhibition by binding to full-length MDM2, increasing p53 activity.
- This suggests potential p53 inactivation or apoptosis contributing to in vivo tumorigenesis.
Conclusions:
- MDM2 splice variants exhibit complex, context-dependent roles in cancer.
- Their therapeutic potential as targets may vary based on their specific phenotype in different tumor types.
- Further research is needed to elucidate both p53-dependent and independent activities.
Related Concept Videos
01:32RNA Splicing
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
02:18Alternative RNA Splicing
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...